Evaluation of the effect of prostaglandin analogues and a carbonic anhydrase inhibitor/β-blocker combination on the ocular blood flow in patients with primary open-angle glaucoma

doi:https://doi.org/10.17116/oftalma201913504170

Close metadata

Recommended articles:

The results of fistulizing glaucoma surgeries in pseudophackic patients. Russian Annals of Ophthalmology. 2025;(1):45-52

The possibilities of antioxidant neuroretinoprotection in the treatment of primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;(4):49-59

Electrophysiological methods in the diagnosis and monitoring of glaucoma. Russian Annals of Ophthalmology. 2025;(4):102-109

The effect of initial conservative hypotensive therapy on the outcomes of selective laser trabeculoplasty in primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;(5):16-22

Modern devices for microinvasive glaucoma surgery. Russian Annals of Ophthalmology. 2025;(5):101-108

Neuroprotective therapy in advanced primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;(6):75-80

Hemodynamic parameters of venous return and their role in assessment of fluid responsiveness in cardiac surgery. Russian Journal of Anesthesiology and Reanimatology. 2025;(2):6-12

Abstract:

Purpose — to assess the effect of latanoprost and fixed combination of dorzolamide/timolol on ocular hemodynamics in patients with primary open-angle glaucoma (POAG). Material and methods. The study examined 34 patients (56 eyes) aged 51 to 69 years (average — 62.4±9.7 years) diagnosed with POAG in the initial (31 eyes) or advanced stage (25 eyes). Patients of the first group (20 patients, 36 eyes) were receiving latanoprost (Glauprost, Rompharm Company, Romania). The second group (14 patients, 20 eyes) was assigned to receive a fixed combination of dorzolamide/timolol (Dorzopt plus, Rompharm Company, Romania). Patient examination before and at 6 and 12 months included tonometry (ICare PRO), perimetry (Heidelberg Edge Perimeter), HRT and OCT of the optic nerve (Heidelberg Retina Tomograph 3 and Spectralis OCT2), as well as measurement of the density of surface (SVL) and deep (DVL) vascular plexus, and the Bruch’s membrane opening minimum rim width (BMO—MRW). Additionally, we evaluated microcirculation in the choroid (MC) according to our original technique that uses Spectralis OCT2, and calculated rheographic index (RI) and stroke volume using transpalpebral rheoophthalmography. Results. The decrease in IOP in the Latanoprost group was on average 27% and in the control group receiving timolol and dorzolamide — on average 22% and remained stable until the end of the study. The value of the area and volume of the disc rim band, BMO—MRW did not exhibit statistically significant changes in both groups by the 12th month of observation. A tendency to increase the RI from 51.5±24.5 to 62.2±19 (p=0.084) and the median of the index of microcirculation of the choroid (MC) from 16476 up to 23767 (p=0.062) in 1st group was observed. Conclusion. The study confirms the feasibility of using latanoprost and a fixed combination of dorzolamide and timolol in ocular hypotensive therapy of glaucoma thanks to their pronounced hypotensive effect. Patients were noted to have a tendency for improvement of ocular hemodynamics when using latanoprost.

Keywords:

glaucoma

latanoprost

dorzolamide

timolol

hemodynamics

Close metadata

References:

Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. British Journal of Ophthalmology. 2006;90(3):262-267.
Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of Ophthalmology. 2002;120(10):1268-1279.
Schmidt KG, Rückmann AV, Mittag TW, Hessemer V, Pillunat LE. Reduced ocular pulse amplitude in low tension glaucoma is independent of vasospasm. Eye (London, England). 1997;11(Pt 4):485-488.
Hayreh SS. Progress in the understanding of the vascular etiology of glaucoma. Current Opinion in Ophthalmology. 1994;5(2):26-35.
Alexeev VV, Strakhov VV, Korchagin NV. Plethysmographic and pathomorphological parallels of reduction of volumetric intraocular blood flow in primary open-angle glaucoma. Klinicheskaya oftal’mologiya. 2010;4(11):120-123. (In Russ.)
Fechtner RD, Weinreb RN. Mechanisms of optic nerve damage in primary open angle glaucoma. Survey of Ophthalmology. 1994;39(1):23-42.
Lovpache DN, Arakelyan MA, Ramazanova KA. Hypotensive efficacy, tolerability and safety of drugs timolol 0.5%, dorzopt 2%, combinations of timolol 0.5% and dorzopt 2% in the treatment of patients with primary open-angle glaucoma. Rossijskij oftal’mologicheskij zhurnal. 2011;4(1):40-43. (In Russ.)
Fuchsjäger-Mayrl G, Wally B, Rainer G, Buehl W, Aggermann T, Kolodjaschna J, Weigert G, Polska E, Eichler HG, Vass C, Schmetterer L. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension. British Journal of Ophthalmology. 2005;89(10):1293-1297.
Siesky B, Harris A, Brizendine E, Marques C, Loh J, Mackey J, Overton J, Netland P. Literature review and meta-analysis of topical carbonic anhydrase inhibitors and ocular blood flow. Survey of Ophthalmology. 2009;54(1):33-46. https://doi.org/10.1016/j.survophthal.2008.06.00210.
Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995;102(12):1743-1752.
Tamaki Y, Nagahara M, Araie M, Tomita K, Sandoh S, Tomidokoro A. Topical latanoprost and optic nerve head and retinal circulation in humans. Journal of Ocular Pharmacology and Therapeutics. 2001;17:403-411. https://doi.org/10.1089/108076801753266785
Stjernschantz J, Selen G, Astin M, Resul B. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment. Progress in Retinal and Eye Research. 2000;19:459-496. https://doi.org/10.1016/S1350-9462(00)00003-3
Okutucu M, Fındık H, Arslan MG. Direct and crossover effects of brinzolamide, betaxolol, and latanoprost on choroidal thickness. Cutaneous and Ocular Toxicology. 2019;1:1-5. https://doi.org/10.1080/15569527.2019.1575390
Fechtner RD, Airaksinen PJ, Getson AJ, Lines CR, Adamsons IA. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus latanoprost 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmologica Scandinavica. 2004;82(1):42-48. https://doi.org/10.1046/j.1600-0420.2004.0205.x.
Zudaire E, Gambardella L, Kurcz C, Vermeren S. A computational tool for quantitative analysis of vascular networks. PLoS One. 2011;6(11):e27385. https://doi.org/10.1371/journal.pone.0027385
Luzhnov PV, Shamaev DM, Iomdina EN, Tarutta EP, Markosyan GA, Shamkina LA, Sianosyan AA. Transpalpebral tetrapolar reoophtalmography in the assessment of parameters of the eye blood circulatory system. Vestnik Rossijskoj akademii medicinskih nauk. 2015;70(3):372-377. (In Russ.)
Parmaksiz S, Yuksel N, Karabas VL, Ozkan B, Demirci G, Caglar Y. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. European Journal of Ophthalmology. 2006;16(1):73-80.
Saltimis M, Orgul S, Doubler B, Flammer J. Rate of progression of glaucoma correlates with retrobulbar circulation and intraocular pressure. American Journal of Ophthalmology. 2003;135(5):664-669.
Bergstrand IC, Heijl A, Harris A. Dorzolamide and ocular blood flow in previously untreated glaucoma patients: a controlled double-masked study. Acta Ophthalmologica Scandinavica. 2002;80(2):176-182.
Martinez A, Sanchez M. Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open-angle glaucoma: a single-center, 4-year, open-label study. Clinical Therapeutics. 2008;30(6):1120-1134. https://doi.org/10.1016/j.clinthera.2008.06.006
Galassi F, Sodi A, Renieri G, Ucci F, Pieri B, Harris A, Siesky B. Effects of timolol and dorzolamide on retrobulbar hemodynamics in patients with newly diagnosed primary open-angle glaucoma. Ophthalmologica. 2002;216(2):123-128. https://doi.org/10.1159/000048311
Hayreh SS, Podhajsky P, Zimmerman MB. Beta-blocker eyedrops and nocturnal arterial hypotension. American Journal of Ophthalmology. 1999;128:301-309.
Lee NY, Park HYL, Park CK. Comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and ocular perfusion pressure in patients with normal-tension glaucoma: a randomized, crossover clinical trial. PLoS One. 2016;11(1):e0146680. https://doi.org/10.1371/journal.pone.0146680
Costagliola C, Parmeggiani F, Virgili G, Lamberti G, Incorvaia C, Perri P, Campa C, Sebastiani A. Circadian changes of intraocular pressure and ocular perfusion pressure after timolol or latanoprost in Caucasians with normal-tension glaucoma. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2008;246(3):389-396.
Gherghel D, Hosking SL, Cunliffe IA, Armstrong RA. First-line therapy with latanoprost 0.005% results in improved ocular circulation in newly diagnosed primary open-angle glaucoma patients: a prospective, 6-month, open-label study. Eye. 2008;22:363-369. https://doi.org/10.1038/sj.eye.6702639
Koz OG, Ozsoy A, Yarangumeli A, Kose SK, Kural G. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial. Acta Ophthalmologica Scandinavica. 2007;85:838-843. https://doi.org/10.1111/j.1600-0420.2007.00960.x
Harris A, Garzozi HJ, McCranor L, Rechtman E, Yung CW, Siesky B. The effect of latanoprost on ocular blood flow. International Ophthalmology. 2009;29(1):19-26. https://doi.org/10.1007/s10792-008-9190-x